Lilly Oncology
在场
Lilly Oncology 的所有者是 Eli Lilly.
是其中之一......
- Forbes Global 2000 (#174);
- Fortune 500 (#127);
- Global Fortune 500 (#455);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly 是一家在股票代码 LLY (US) 下上市的公司。
Eli Lilly 在 18 个国家有直接业务。Eli Lilly 拥有 25家子公司，其中包括 Dice Therapeutics、Eli Lilly APAC 和 Eli Lilly Argentina。
他们在：
涉及Eli Lilly的并购和融资。
- Eli Lilly 已收购 Morphic Therapeutic (公布2024八月20号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十二月5号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十月6号).
- Eli Lilly 已收购 Versanis Bio (公布2023八月15号).
- Eli Lilly has announced the acquisition of Versanis Bio (公布2023七月18号).
- Eli Lilly has announced the acquisition of Sigilon Therapeutics (公布2023六月30号).
- Eli Lilly has announced the acquisition of Dice Therapeutics (公布2023六月22号).
- 查看更多"Eli Lilly"相关新闻 Hide news involving Eli Lilly
高管
查看带有其 4 名主要高管的组织结构图
Lilly Oncology 搜索最多的简介
- Joe Mccann, Senior Vice President and Managing Director
- Dan Davis, Associate Vice President, Medical
- Myra Herrle, Vice President, Regulatory Affairs
高管在Eli Lilly变化
- Jon MoellerJon Moeller 将于202412月31作为 Director 加入公司 (新闻发布的2024十一月20号).
- Thomas FuchsThomas Fuchs 将于202410月21作为 Chief Artificial Intelligence Officer 加入公司 (新闻发布的2024十月9号).
- Marschall Runge, Director, 将于 20248月31 退休 (新闻发布的2024八月20号).
创建提醒
跟踪 Lilly Oncology 的高管变动
药店
Eli Lilly 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Lilly Oncology 的最新新闻稿
- Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines | Eli Lilly and Company
- U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis | Eli Lilly and Company
- Eli Lilly and Company Statement on ICER Final Report for Acute Treatments for Migraine: Effectiveness and Value | Eli Lilly and Company
- Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease | Eli Lilly and Company
- Lilly to Participate in Cowen Health Care Conference | Eli Lilly and Company
- Lilly Completes Acquisition of Dermira | Eli Lilly and Company
- Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study | Eli Lilly and Company
- Lilly to Participate in Guggenheim Healthcare Talks Idea Forum | Eli Lilly and Company
- CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes | Eli Lilly and Company
- Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition | Eli Lilly and Company
- View more press releases Close
通过电子邮件
